The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) demonstrated that the angiotensinconverting enzyme inhibitor, perindopril, compared with placebo, in patients with established coronary artery disease, reduced cardiovascular endpoints by 20% over a four-year follow-up period. Although the authors of this study claim that the risk reduction was best explained by blockade of the renin-angiotensinaldosterone system, reference to recent meta-analyses of blood pressure (BP)-lowering trials provides compelling evidence that the benefits observed in the trial could be explained by the 5/2 mmHg BP difference between active and placebo treatments.
A frustrating issue raised in a previous commentary in this journal 1 was the lack of evidence on coronary heart disease (CHD) outcome from randomised placebo-controlled trials with angiotensin-converting enzyme (ACE) inhibitors in hypertensive patients. The early placebo-controlled trials with older antihypertensive agents such as diuretics and β-blocking drugs provided good evidence of stroke protection compared with expectations based on observational data, 2 but a shortfall in protection against CHD events 3 ascribed by many to limitations of older drugs on account of their adverse metabolic profile. 4, 5 Expectations that newer blood pressure (BP)lowering drugs, such as ACE inhibitors [ACE-Is] and calcium channel blocking drugs [CCBs], would overcome some of these problems were not accompanied by commitments from their manufacturers to conduct placebo-controlled morbidity and mortality outcome trials in hypertensive patients, which at the time would have been ethically justifiable, at least in some hypertensive subgroups and would have contributed importantly to the evidence base.
The only exception was the Systolic hypertension in Europe (Syst-Eur) trial 6 with the dihydropyridine CCB, nitrendipine, which did demonstrate a reduction in total cardiac events compared with placebo, in patients with isolated systolic hypertension.
With mounting evidence from experimental studies and studies on surrogate endpoints 7,8 that blocking the renin-angiotensin-aldosterone system (RAAS) might confer benefits over and above those related to BP-lowering, it was particularly important that a placebo-controlled outcome trial should have been carried out, not least because of the substantial cost differential with older drugs used for the treatment of hypertension.
Several trials in hypertensive patients compared different active treatments including ACE-I and CCB-based regimens with older drugs, but most of these studies were grossly underpowered to detect any differential outcome on CHD events and so, not surprisingly, they did not! 9,10,11,12 A single large trial, Antihypertensive and Lipid Lowering treatment to prevent Heart Attack (ALLHAT), showed no difference on CHD outcome when an ACE-I-based regimen was compared with a thiazide-like diuretic. 13 However, these results were confounded by differential effects on BP, owing to the age and ethnic composition of the trial population and possible other factors. Nevertheless, there was no evidence of any benefit associated with the ACE-I used.
Several meta-analyses have attempted to evaluate optimal first-line therapy with the most recent again suggesting that most, if not all the benefit on CHD and other cardiovascular events including stroke, is related to BP-lowering and not to any specific effects of drug class, including those that block the RAAS. 14 Unfortunately, most of the evidence for ACE-I incorporated into the meta-analyses comes from placebo-controlled trials in patients with established cardiovascular disease who were not recruited on the basis that they were hypertensive.
So what then do we make of the EUROPA findings?
The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA), 15 like the Heart Outcomes Prevention Evaluation (HOPE) study, 16 was a placebo-controlled study in patients at high cardiovascular risk. In EUROPA, the ACE-I, perindopril, was compared with placebo in over 12,000 patients with established CHD (prior myocardial infarction (MI) -65%, angiographic CHD -50%, positive stress test -23%). In just over four years, perindopril reduced a combined endpoint of cardiovascular (CV) death, non-fatal MI and cardiac arrest by 20% compared with placebo, a result broadly compatible with the benefits seen with ramipril in the HOPE study, albeit in a somewhat different but essentially high CV risk population. In EUROPA, benefits were similar amongst prespecified subgroups including those with and without hypertension. As with the interpretation of the HOPE study, there has been much debate over whether the benefits in reducing CHD events are due to BPlowering or to RAAS blockade. 17 The authors of HOPE repeatedly disclaim that lowering BP accounted for the benefits observed. The nocturnal administration of ramipril (a short acting ACE-I), casual unstructured daytime BP readings (3/2 mmHg lower on ramipril) and a 24-hour ambulatory BP sub-study 18 showing an average reduction in systolic pressure of 11 mmHg throughout the monitoring period in those assigned ramipril would suggest otherwise, namely that BP differences could have substantially, if not totally explained the outcome.
In EUROPA, clinic BPs were reported as being, on average, 5/2 mmHg higher in the placebo group. We are not told whether the differences were greater early in the trial. The authors of the trial and those of the accompanying commentary in the Lancet 19 dismiss BP reduction as an explanation for the CHD protection, on the grounds that the magnitude of the benefit was greater than might be expected for the difference in BP. However, to support their claim, they quote observational data derived from totally different populations at much lower cardiovascular risk and whose applicability to the high-risk patients selected for EUROPA is at best uncertain.
The most recent meta-analysis of intervention studies from the Blood Pressure Lowering Treatment Trialists' Collaboration provides an evidence-base that, in contrast, would support the view that the benefits observed in EUROPA are more than likely compatible with the differences in BP achieved. 14 In this analysis of placebo-controlled trials with ACE-I, the pooled estimate for CHD reduction associated with a 5/2 mmHg reduction in BP is precisely the benefit observed in EUROPA viz: 20%.
Two outstanding trials will shed further light on this controversial issue. Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial 20 completes patient assessment in December 2003.This trial in hypertensive patients compares an angiotensin receptor blocker (valsartan) with a CCB, amlodipine and is powered to detect a 15% difference in cardiac morbidity and mortality.
The Anglo Scandinavian Cardiac Outcomes Trial (ASCOT), 21 due to complete in 2004/5 compares an older regimen of β-blocker/diuretic with a CCB/ACE-I regimen (85% of patients are on the ACE-I) in over 19,000 hypertensive subjects at modest risk of CHD (circa 1% per year) and is powered to detect a 20% relative difference in CHD outcome between the two groups.
For the time being, the debate will go on. Is it BP or is it drug class? The wisdom of hindsight tells us that we may have missed the boat to answer this question. We may be proved wrong. 
